177 related articles for article (PubMed ID: 17406356)
1. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum.
Belinsky SA; Grimes MJ; Casas E; Stidley CA; Franklin WA; Bocklage TJ; Johnson DH; Schiller JH
Br J Cancer; 2007 Apr; 96(8):1278-83. PubMed ID: 17406356
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
[TBL] [Abstract][Full Text] [Related]
3. Gene promoter methylation in plasma and sputum increases with lung cancer risk.
Belinsky SA; Klinge DM; Dekker JD; Smith MW; Bocklage TJ; Gilliland FD; Crowell RE; Karp DD; Stidley CA; Picchi MA
Clin Cancer Res; 2005 Sep; 11(18):6505-11. PubMed ID: 16166426
[TBL] [Abstract][Full Text] [Related]
4. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC.
Olaussen KA; Soria JC; Park YW; Kim HJ; Kim SH; Ro JY; André F; Jang SJ
Eur J Cancer; 2005 Sep; 41(14):2112-9. PubMed ID: 16129599
[TBL] [Abstract][Full Text] [Related]
5. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
6. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study.
Cirincione R; Lintas C; Conte D; Mariani L; Roz L; Vignola AM; Pastorino U; Sozzi G
Int J Cancer; 2006 Mar; 118(5):1248-53. PubMed ID: 16152615
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
8. Variability in the measurement of the methylation status of lung cancer-related genes in bronchial secretions.
Millares L; Rosell A; Setó L; Sanz J; Andreo F; Monsó E
Oncol Rep; 2014 Oct; 32(4):1435-40. PubMed ID: 25069886
[TBL] [Abstract][Full Text] [Related]
9. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.
Belinsky SA; Liechty KC; Gentry FD; Wolf HJ; Rogers J; Vu K; Haney J; Kennedy TC; Hirsch FR; Miller Y; Franklin WA; Herman JG; Baylin SB; Bunn PA; Byers T
Cancer Res; 2006 Mar; 66(6):3338-44. PubMed ID: 16540689
[TBL] [Abstract][Full Text] [Related]
11. [Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers].
Peng Z; Shan C; Wang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Mar; 35(3):247-53. PubMed ID: 20360646
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
13. Serum DNA as a tool for cancer patient management.
Ramirez JL; Taron M; Balaña C; Sarries C; Mendez P; de Aguirre I; Nuñez L; Roig B; Queralt C; Botia M; Rosell R
Rocz Akad Med Bialymst; 2003; 48():34-41. PubMed ID: 14737938
[TBL] [Abstract][Full Text] [Related]
14. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers.
Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA
Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700
[TBL] [Abstract][Full Text] [Related]
15. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
Konno S; Morishita Y; Fukasawa M; Shu Y; Wang D; Tanaka R; Minami Y; Iijima T; Noguchi M
Cancer; 2004 Dec; 102(6):348-54. PubMed ID: 15481085
[TBL] [Abstract][Full Text] [Related]
16. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
[TBL] [Abstract][Full Text] [Related]
17. Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano WA; Divine KK; Saccomanno G; Gilliland FD; Baylin SB; Herman JG; Belinsky SA
Cancer Res; 2000 Nov; 60(21):5954-8. PubMed ID: 11085511
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer?
de Fraipont F; Moro-Sibilot D; Michelland S; Brambilla E; Brambilla C; Favrot MC
Lung Cancer; 2005 Nov; 50(2):199-209. PubMed ID: 16043258
[TBL] [Abstract][Full Text] [Related]
19. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum.
Gilliland FD; Harms HJ; Crowell RE; Li YF; Willink R; Belinsky SA
Cancer Res; 2002 Apr; 62(8):2248-52. PubMed ID: 11956078
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.
De Jong WK; Verpooten GF; Kramer H; Louwagie J; Groen HJ
Anticancer Res; 2009 Jan; 29(1):363-9. PubMed ID: 19331174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
